CSIMarket
 


Candel Therapeutics Inc   (CADL)
Other Ticker:  
 
 

CADL's Operating Income Growth by Quarter and Year

Candel Therapeutics Inc 's Operating Income results by quarter and year




CADL Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 13.33 0.00 0.00
III Quarter September -8.88 -8.03 0.00 0.00
II Quarter June -8.75 -5.30 0.00 0.00
I Quarter March -8.99 0.00 0.00 0.00
FY   -26.62 0.00 0.00 0.00



CADL Operating Income third quarter 2022 Y/Y Growth Comment
Candel Therapeutics Inc in the third quarter 2022 recorded Operating Loss of $ -8.88 millions.

According to the results reported in the third quarter 2022, Candel Therapeutics Inc achieved the best Operating Income growth in Biotechnology & Pharmaceuticals industry. While Candel Therapeutics Inc ' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2022.

Explain Operating Income growth


CADL Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Candel Therapeutics Inc 's third quarter 2022 Operating Income $ -8.88 millions CADL's Income Statement
Candel Therapeutics Inc 's third quarter 2021 Operating Income $ -8.03 millions Quarterly CADL's Income Statement
New: More CADL's historic Operating Income Growth >>


CADL Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Candel Therapeutics Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CADL's III. Quarter Q/Q Operating Income Comment
III. Quarter 2022 Operating Loss of -8.88 millions by Candel Therapeutics Inc appear even less good if you take a look at Operating Loss -8.75 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Candel Therapeutics Inc achieved highest sequential Operating Income growth. While Candel Therapeutics Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CADL's III. Quarter Q/Q Operating Income Comment
Current Operating Loss of -8.88 millions by Candel Therapeutics Inc appear even worse considering the Operating Loss -8.75 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Candel Therapeutics Inc achieved highest sequential Operating Income growth. While Candel Therapeutics Inc 's Operating Income growth quarter on quarter, overall rank is .


Candel Therapeutics Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Operating Income 12 Months Ending $ -13.29 $ -12.44 $ -8.99 $ 0.00 $ 0.00
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Candel Therapeutics Inc ' has realized cumulative trailing twelve months Operating Loss of $ -13 millions in the Sep 30 2022 period.
The business is detiriorating as the cumulative Operating Loss is inflating from $ -12.44 millions for the period from Jun 30 2022 to Sep 30 2021 and $ -8.75 millions from the TTM period ending Sep 30 2021.

Candel Therapeutics Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Candel Therapeutics Inc ' has realized cumulative trailing twelve months Operating Loss of $ -13 millions in the Sep 30 2022 period.
The business is detiriorating as the cumulative Operating Loss is becoming larger from $ -12.44 millions in TTM ending quarter Jun 30 2022 and $ -8.75 millions from the TTM period ending Sep 30 2021 Margaux Simon wrote.

Candel Therapeutics Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
CADL's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for CADL's Competitors
Operating Income Growth for Candel Therapeutics Inc 's Suppliers
Operating Income Growth for CADL's Customers

You may also want to know
CADL's Annual Growth Rates CADL's Profitability Ratios CADL's Asset Turnover Ratio CADL's Dividend Growth
CADL's Roe CADL's Valuation Ratios CADL's Financial Strength Ratios CADL's Dividend Payout Ratio
CADL's Roa CADL's Inventory Turnover Ratio CADL's Growth Rates CADL's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2022
Bristol myers Squibb Company18.36%$ 18.364 millions
Merit Medical Systems Inc17.11%$ 17.111 millions
Repligen Corp16.53%$ 16.531 millions
Surgery Partners Inc 16.51%$ 16.509 millions
Avantor Inc 16.27%$ 16.273 millions
Bruker Corporation15.99%$ 15.989 millions
Integra Lifesciences Holdings Corp15.26%$ 15.255 millions
Option Care Health Inc 14.82%$ 14.816 millions
Zimmer Biomet Holdings Inc 14.15%$ 14.146 millions
Acadia Healthcare Company Inc 13.82%$ 13.821 millions
Sonida Senior Living Inc 13.67%$ 13.667 millions
Ensign Group Inc12.02%$ 12.016 millions
Globus Medical Inc 11.95%$ 11.950 millions
Mettler Toledo International Inc10.44%$ 10.436 millions
Halozyme Therapeutics Inc 10.20%$ 10.195 millions
Assertio Holdings inc 8.43%$ 8.426 millions
Prestige Consumer Healthcare Inc 7.42%$ 7.416 millions
Organon and Co 6.92%$ 6.925 millions
Abbvie Inc 6.90%$ 6.897 millions
Vertex Pharmaceuticals Inc6.85%$ 6.846 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

EVOA's Profile

Stock Price

EVOA's Financials

Business Description

Fundamentals

Charts & Quotes

EVOA's News

Suppliers

EVOA's Competitors

Customers & Markets

Economic Indicators

EVOA's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071